NeuroOne CAO granted options on 12,500 shares

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Administrative Officer Emily J. Johns received a grant of stock options.

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported that Chief Administrative Officer Emily J. Johns received a grant of stock options. The award covers 12,500 options to purchase common shares at an exercise price of $1.77 per share, expiring on August 27, 2036. Following this grant, she holds 12,500 options. According to the vesting terms, 25% of the options will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments thereafter.

Insider Trade Summary

Grant/Award: 12,500 shares

Grant/Award 1 txn

Insider Johns Emily J.

Role Chief Administrative Officer

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock F1	12,500	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 12,500 contracts (Direct)

Footnotes (1)

1. F1. 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.

Key Figures

Options Granted: 12,500 options Exercise Price: $1.77 per share Expiration Date: August 27, 2036 +3 more

6 metrics

Options Granted 12,500 options Grant of options to purchase NMTC common stock reported by Emily J. Johns

Exercise Price $1.77 per share Conversion or exercise price of the newly granted options

Expiration Date August 27, 2036 Expiration date of the reported stock option grant

Initial Vesting Portion 25% Portion of options vesting on August 28, 2027

Remaining Vesting Portion 75% Portion of options vesting in 12 equal quarterly installments after August 28, 2027

Underlying Shares 12,500 shares Common shares underlying the reported stock options

Key Terms

Option to Purchase Common Stock, vesting, quarterly installments

3 terms

Option to Purchase Common Stock financial

"security_title: Option to Purchase Common Stock"

vesting financial

"25% will vest on August 28, 2027, and the remaining 75% will vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

quarterly installments financial

"the remaining 75% will vest in 12 equal quarterly installments"

FAQ

What insider transaction did NMTC report for Emily J. Johns?

NMTC reported that Emily J. Johns, Chief Administrative Officer, received a grant of 12,500 stock options to purchase common stock at an exercise price of $1.77 per share, expiring on August 27, 2036. This award was reported as an acquisition of derivative securities.

What is the exercise price of the new NMTC stock options granted to Emily J. Johns?

The stock options granted to Emily J. Johns have an exercise price of $1.77 per share for NMTC common stock. This price applies to all 12,500 options covered by the reported award.

How many NMTC options does Emily J. Johns hold after this transaction?

After the reported transaction, Emily J. Johns holds 12,500 options to purchase NMTC common stock. The filing lists these options as held with direct ownership following the grant.

What are the vesting terms of Emily J. Johns’s NMTC option grant?

The vesting terms state that 25% of the options will vest on August 28, 2027. The remaining 75% will vest in 12 equal quarterly installments after that date, leading to gradual vesting over time.

When do the newly granted NMTC options to Emily J. Johns expire?

The newly granted NMTC options to Emily J. Johns expire on August 27, 2036. Until that expiration date, vested options may be exercisable at the stated exercise price of $1.77 per share according to the award terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 05:29 PM Accepted by SEC EDGAR 08/28/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johns Emily J.

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MINNESOTA 55344

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$1.77	08/28/2026		A		12,500		(1)	08/27/2036	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.

	/s/ Emily Johns	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)